Nivolumab to control molecular response in chronic myeloid leukemia

Leuk Res. 2018 Sep:72:5-6. doi: 10.1016/j.leukres.2018.07.011. Epub 2018 Jul 26.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Aged, 80 and over
  • Humans
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / blood
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy*
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / pathology
  • Male
  • Melanoma / blood
  • Melanoma / drug therapy*
  • Melanoma / pathology
  • Neoplasm, Residual
  • Neoplasms, Second Primary / blood
  • Neoplasms, Second Primary / drug therapy*
  • Neoplasms, Second Primary / pathology
  • Nivolumab / administration & dosage*

Substances

  • Nivolumab